Provided by Tiger Trade Technology Pte. Ltd.

Kura Oncology

11.89
+0.18001.54%
Post-market: 11.900.0100+0.08%19:54 EDT
Volume:2.03M
Turnover:24.18M
Market Cap:1.06B
PE:-3.53
High:12.25
Open:11.78
Low:11.67
Close:11.71
52wk High:12.90
52wk Low:7.36
Shares:88.77M
Float Shares:70.60M
Volume Ratio:0.71
T/O Rate:2.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3668
EPS(LYR):-3.1784
ROE:-167.71%
ROA:-31.30%
PB:21.79
PE(LYR):-3.74

Loading ...

Kura Oncology Q2 Net Income USD -68.327 Million

THOMSON REUTERS
·
Aug 13

Kura Oncology, Inc. Expected to Post a Loss of 88 Cents a Share - Earnings Preview

Reuters
·
Aug 11

Kura Oncology Highlights Ziftomenib Preclinical Activity, Menin Binding Profile in Blood Publication

Reuters
·
Aug 10

Kura Oncology Grants Inducement Stock Options for 104,500 Shares at $9.19 Each

Reuters
·
Aug 07

Kura Oncology Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 07

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 07

Kura Oncology to Report Second Quarter Financial Results

GlobeNewswire
·
Aug 05

Kura Oncology Updates CEO Troy Wilson Severance Terms in Revised Employment Agreement

Reuters
·
Jul 30

Wedbush Keeps Their Buy Rating on Kura Oncology (KURA)

TIPRANKS
·
Jul 28

Kura Oncology Price Target Maintained with a $36.00/Share by Wedbush

Dow Jones
·
Jul 28

Charles Zhu Maintains Buy Rating on Kura Oncology, Reiterates $28 Price Target on Encouraging Darlifarnib Combination Data

TIPRANKS
·
Jul 28

Kura Oncology announces durable activity of darlifarnib combination in ccRCC

TIPRANKS
·
Jul 27

Kura Oncology Reports up to 50% Response Rate for Darlifarnib-cabozantinib Combo in Phase 1a Kidney Cancer Trial

Reuters
·
Jul 27

Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-NaÏVe Clear Cell Renal Cell Carcinoma Patients at Kcrs 2026

THOMSON REUTERS
·
Jul 27

Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026

GlobeNewswire
·
Jul 27

Kura Oncology (KURA) Receives a New Rating from a Top Analyst

TIPRANKS
·
Jul 20

Kura Oncology Announces Availability of Press Release on Darlifarnib-cabozantinib RCC Data Update

Reuters
·
Jul 14

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

GlobeNewswire
·
Jul 14

Kura Oncology Grants Inducement Stock Options for 68,750 Shares at $10.78 Each

Reuters
·
Jul 03

Kura Oncology Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 03